CA2685407A1 - Procedes et compositions destines a stimuler et a preserver la croissance osseuse - Google Patents

Procedes et compositions destines a stimuler et a preserver la croissance osseuse Download PDF

Info

Publication number: CA2685407A1
Authority: CA; Canada
Prior art keywords: bone; subject; agent; parathyroid hormone; calcitonin
Prior art date: 2007-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002685407A

Other languages

English (en)

Inventor

Agnes Vignery

Nozer M. Mehta

James P. Gilligan

Kieran P. Murphy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yale University

Kieran Murphy LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-27

Filing date

2007-04-27

Publication date

2008-11-06

2007-04-27 Application filed by Individual filed Critical Individual

2008-11-06 Publication of CA2685407A1 publication Critical patent/CA2685407A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract 31
230000008468 bone growth Effects 0.000 title claims abstract 4
239000000203 mixture Substances 0.000 title 1
210000000988 bone and bone Anatomy 0.000 claims abstract 39
239000003795 chemical substances by application Substances 0.000 claims abstract 17
229940124325 anabolic agent Drugs 0.000 claims abstract 12
239000003263 anabolic agent Substances 0.000 claims abstract 12
230000003416 augmentation Effects 0.000 claims abstract 8
239000000560 biocompatible material Substances 0.000 claims abstract 7
239000008280 blood Substances 0.000 claims abstract 7
210000004369 blood Anatomy 0.000 claims abstract 7
230000000123 anti-resoprtive effect Effects 0.000 claims abstract 6
230000000694 effects Effects 0.000 claims abstract 5
210000000963 osteoblast Anatomy 0.000 claims abstract 5
230000003190 augmentative effect Effects 0.000 claims abstract 2
230000015572 biosynthetic process Effects 0.000 claims abstract 2
230000001939 inductive effect Effects 0.000 claims abstract 2
102000003982 Parathyroid hormone Human genes 0.000 claims 18
108090000445 Parathyroid hormone Proteins 0.000 claims 18
239000000199 parathyroid hormone Substances 0.000 claims 18
229960001319 parathyroid hormone Drugs 0.000 claims 18
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 8
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 6
108010068072 salmon calcitonin Proteins 0.000 claims 6
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 4
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 4
239000002639 bone cement Substances 0.000 claims 4
102000055006 Calcitonin Human genes 0.000 claims 3
108060001064 Calcitonin Proteins 0.000 claims 3
102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 3
238000002347 injection Methods 0.000 claims 3
239000007924 injection Substances 0.000 claims 3
102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 2
102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
108700020797 Parathyroid Hormone-Related Proteins 0.000 claims 2
102000043299 Parathyroid hormone-related Human genes 0.000 claims 2
102000019307 Sclerostin Human genes 0.000 claims 2
108050006698 Sclerostin Proteins 0.000 claims 2
101710142969 Somatoliberin Proteins 0.000 claims 2
102000013275 Somatomedins Human genes 0.000 claims 2
108010009583 Transforming Growth Factors Proteins 0.000 claims 2
102000009618 Transforming Growth Factors Human genes 0.000 claims 2
239000012190 activator Substances 0.000 claims 2
210000001185 bone marrow Anatomy 0.000 claims 2
229960004015 calcitonin Drugs 0.000 claims 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
229940126864 fibroblast growth factor Drugs 0.000 claims 2
229940088597 hormone Drugs 0.000 claims 2
239000005556 hormone Substances 0.000 claims 2
230000000921 morphogenic effect Effects 0.000 claims 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
108090000623 proteins and genes Proteins 0.000 claims 2
102000004169 proteins and genes Human genes 0.000 claims 2
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical group C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 2
VUBUAHHUDGCHIN-LPJXTDOQSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]butanedioic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VUBUAHHUDGCHIN-LPJXTDOQSA-N 0.000 claims 1
229940122361 Bisphosphonate Drugs 0.000 claims 1
KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
102000008186 Collagen Human genes 0.000 claims 1
108010035532 Collagen Proteins 0.000 claims 1
102000009123 Fibrin Human genes 0.000 claims 1
108010073385 Fibrin Proteins 0.000 claims 1
102000008946 Fibrinogen Human genes 0.000 claims 1
108010049003 Fibrinogen Proteins 0.000 claims 1
101000741447 Gallus gallus Calcitonin Proteins 0.000 claims 1
102000018997 Growth Hormone Human genes 0.000 claims 1
108010051696 Growth Hormone Proteins 0.000 claims 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 1
102000016267 Leptin Human genes 0.000 claims 1
108010092277 Leptin Proteins 0.000 claims 1
108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 claims 1
208000002193 Pain Diseases 0.000 claims 1
229930003316 Vitamin D Natural products 0.000 claims 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
230000004075 alteration Effects 0.000 claims 1
230000001195 anabolic effect Effects 0.000 claims 1
150000004663 bisphosphonates Chemical group 0.000 claims 1
210000000459 calcaneus Anatomy 0.000 claims 1
230000001126 calcilytic effect Effects 0.000 claims 1
239000001506 calcium phosphate Substances 0.000 claims 1
229910000389 calcium phosphate Inorganic materials 0.000 claims 1
235000011010 calcium phosphates Nutrition 0.000 claims 1
239000001175 calcium sulphate Substances 0.000 claims 1
235000011132 calcium sulphate Nutrition 0.000 claims 1
XFWJKVMFIVXPKK-UHFFFAOYSA-N calcium;oxido(oxo)alumane Chemical compound [Ca+2].[O-][Al]=O.[O-][Al]=O XFWJKVMFIVXPKK-UHFFFAOYSA-N 0.000 claims 1
229920001436 collagen Polymers 0.000 claims 1
239000000512 collagen gel Substances 0.000 claims 1
239000004053 dental implant Substances 0.000 claims 1
230000001076 estrogenic effect Effects 0.000 claims 1
229940012952 fibrinogen Drugs 0.000 claims 1
239000000122 growth hormone Substances 0.000 claims 1
229940045644 human calcitonin Drugs 0.000 claims 1
210000002758 humerus Anatomy 0.000 claims 1
229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
239000003112 inhibitor Substances 0.000 claims 1
229940039781 leptin Drugs 0.000 claims 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
230000011164 ossification Effects 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
150000003180 prostaglandins Chemical class 0.000 claims 1
230000000541 pulsatile effect Effects 0.000 claims 1
230000011664 signaling Effects 0.000 claims 1
238000005728 strengthening Methods 0.000 claims 1
229910052712 strontium Inorganic materials 0.000 claims 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
230000008685 targeting Effects 0.000 claims 1
210000002303 tibia Anatomy 0.000 claims 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
235000019166 vitamin D Nutrition 0.000 claims 1
239000011710 vitamin D Substances 0.000 claims 1
150000003710 vitamin D derivatives Chemical class 0.000 claims 1
229940046008 vitamin d Drugs 0.000 claims 1
JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Dental Preparations (AREA)
Surgical Instruments (AREA)

CA002685407A 2007-04-27 2007-04-27 Procedes et compositions destines a stimuler et a preserver la croissance osseuse Abandoned CA2685407A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2007/010267 WO2008133618A1 (fr)	2007-04-27	2007-04-27	Procédés et compositions destinés à stimuler et à préserver la croissance osseuse

Publications (1)

Publication Number	Publication Date
CA2685407A1 true CA2685407A1 (fr)	2008-11-06

Family

ID=39925939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002685407A Abandoned CA2685407A1 (fr)	2007-04-27	2007-04-27	Procedes et compositions destines a stimuler et a preserver la croissance osseuse

Country Status (6)

Country	Link
EP (1)	EP2139507A4 (fr)
JP (1)	JP2010526064A (fr)
CN (1)	CN101663043B (fr)
AU (1)	AU2007352435B2 (fr)
CA (1)	CA2685407A1 (fr)
WO (1)	WO2008133618A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3345607T (lt)	2006-12-29	2023-01-10	Ossifi-Mab Llc	Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą
CN101966348B (zh) *	2010-09-21	2014-03-26	中国科学院深圳先进技术研究院	掺锶羟基磷灰石胶原复合材料及其应用和制备方法
TWI573558B (zh) *	2015-09-30	2017-03-11	愛派司生技股份有限公司	一種含具有複數螺紋區之骨螺釘的骨板組

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8724897D0 (en) *	1987-10-23	1987-11-25	Downes S	Material
EP1272131B1 (fr) *	2000-04-05	2006-03-01	Kyphon Inc.	Dispositifs destines au traitement d'os fractures et/ou malades
WO2002032827A1 (fr) *	2000-10-16	2002-04-25	The University Of South Carolina	Ciment biocompatible contenant des nanoparticules reactives de phosphate de calcium et procedes de fabrication et d'utilisation d'un tel ciment
JP2004526747A (ja) *	2001-04-03	2004-09-02	ザロイヤルアレクサンドラホスピタルフォーチルドレン	骨移植で使用される医薬
CN1294885C (zh) *	2001-06-05	2007-01-17	江苏阳生生物工程有限公司	人体骨组织生物工程支架制品及其制备方法和用途
TWI267378B (en) *	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
EP1446445A4 (fr) *	2001-09-21	2007-04-04	Stryker Corp	Agents porogenes pour ciments orthopediques
CN1622826A (zh) *	2002-01-17	2005-06-01	德克萨斯系统大学董事会	用凝血酶肽衍生物刺激骨生长和软骨形成
SE0300620D0 (sv) *	2003-03-05	2003-03-05	Bone Support Ab	A new bone substitute composition
US9532994B2 (en) *	2003-08-29	2017-01-03	The Regents Of The University Of California	Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US7531518B2 (en) *	2004-05-14	2009-05-12	Unigene Laboratories Inc.	Method for fostering bone formation and preservation
US7175858B2 (en) *	2004-07-26	2007-02-13	Skeletal Kinetics Llc	Calcium phosphate cements and methods for using the same
US20060089723A1 (en) *	2004-10-25	2006-04-27	Murphy Kieran P	Method for bone augmentation
JP5328153B2 (ja) *	2005-01-06	2013-10-30	バクスター・インターナショナル・インコーポレーテッド	骨折修復のための強化（ｓｕｐｐｌｅｍｅｎｔｅｄ）マトリックス
JP2006263184A (ja) *	2005-03-24	2006-10-05	Gc Corp	骨セメント注入充填方法及び骨セメント注入充填用漏洩防止袋
EP1879608A4 (fr) *	2005-05-11	2009-11-11	Unigene Lab Inc	Methode pour stimuler la formation et la preservation des os
US20060293667A1 (en) *	2005-05-19	2006-12-28	Agnes Vignery	Bone implant device and methods of using same
US7691105B2 (en) *	2005-09-26	2010-04-06	Depuy Spine, Inc.	Tissue augmentation, stabilization and regeneration technique

2007
- 2007-04-27 EP EP07776368A patent/EP2139507A4/fr not_active Withdrawn
- 2007-04-27 AU AU2007352435A patent/AU2007352435B2/en not_active Ceased
- 2007-04-27 WO PCT/US2007/010267 patent/WO2008133618A1/fr active Application Filing
- 2007-04-27 JP JP2010506155A patent/JP2010526064A/ja active Pending
- 2007-04-27 CA CA002685407A patent/CA2685407A1/fr not_active Abandoned
- 2007-04-27 CN CN200780052739.5A patent/CN101663043B/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2139507A1 (fr)	2010-01-06
AU2007352435B2 (en)	2012-01-19
CN101663043A (zh)	2010-03-03
WO2008133618A1 (fr)	2008-11-06
EP2139507A4 (fr)	2012-06-06
JP2010526064A (ja)	2010-07-29
CN101663043B (zh)	2014-03-12
AU2007352435A1 (en)	2008-11-06

Publication	Publication Date	Title
Vukicevic et al.	2014	The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing
Ejersted et al.	1993	Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats
Solheim	1998	Growth factors in bone
US8690874B2 (en)	2014-04-08	Composition and process for bone growth and repair
ES2325573T3 (es)	2009-09-09	Granulos porosos de fosfato tricalcico beta y metodos para produccion de los mismos.
US8048857B2 (en)	2011-11-01	Flowable carrier compositions and methods of use
IL110350A (en)	2002-02-10	Medical combination of the parathyroid hormone and relaxoxin to freeze bone mass
CN101222881A (zh)	2008-07-16	骨植入体器械及其使用方法
HUP0303013A2 (hu)	2003-12-29	Gyógyszer csontelhalás kezelésére és olyan betegek gondozására, akiknél a csontelhalás kialakulásának kockázata áll fenn
KR20100026910A (ko)	2010-03-10	서방형 골다공증치료제를 담지한 골충진재
US20150125457A1 (en)	2015-05-07	Bone repair promoter
US12234269B2 (en)	2025-02-25	Osteogenic biomaterial
JP2011510066A5 (fr)	2012-02-16
Tekin et al.	2008	Effects of alendronate on rate of distraction in rabbit mandibles
Kirker-Head et al.	2007	Use of bone morphogenetic proteins for augmentation of bone regeneration
US8852240B2 (en)	2014-10-07	Methods and compositions for fostering and preserving bone growth
CA2685407A1 (fr)	2008-11-06	Procedes et compositions destines a stimuler et a preserver la croissance osseuse
Clarke et al.	2004	The effect of osteogenic growth factors on bone growth into a ceramic filled defect around an implant
Aleksynienė et al.	2004	Parathyroid hormone–possible future drug for orthopedic surgery
Puleo	2003	Biotherapeutics in orthopaedic medicine: accelerating the healing process?
Richards	2008	The relevance of implant surfaces in hand fracture fixation
Song et al.	2024	Methods to Enhance Bone Formation in Distraction Osteogenesis
Ahmadpour et al.	2025	Local Delivery of Various Hormonal Drugs Along With Bone Grafts to Improve Osteogenesis: A Systematic Review
Grzeskowiak	2020	Surgical implant and tissue interface
Lachman et al.	2021	Bone Healing

Legal Events

Date	Code	Title	Description
2009-10-27	EEER	Examination request
2015-11-05	FZDE	Dead	Effective date: 20150910